Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Jul 28;13(4):234.
doi: 10.1186/ar3379.

Negative regulation of osteoclastogenesis and bone resorption by cytokines and transcriptional repressors

Baohong Zhao  1 , Lionel B Ivashkiv
Affiliations
Review

Negative regulation of osteoclastogenesis and bone resorption by cytokines and transcriptional repressors

Baohong Zhao et al. Arthritis Res Ther. .

Abstract

Bone remodeling in physiological and pathological conditions represents a balance between bone resorption mediated by osteoclasts and bone formation by osteoblasts. Bone resorption is tightly and dynamically regulated by multiple mediators, including cytokines that act directly on osteoclasts and their precursors, or indirectly by modulating osteoblast lineage cells that in turn regulate osteoclast differentiation. The critical role of cytokines in inducing and promoting osteoclast differentiation, function and survival is covered by the accompanying review by Zwerina and colleagues. Recently, it has become clear that negative regulation of osteoclastogenesis and bone resorption by inflammatory factors and cytokines, downstream signaling pathways, and a newly described network of transcriptional repressors plays a key role in bone homeostasis by fine tuning bone remodeling and restraining excessive bone resorption in inflammatory settings. In this review we discuss negative regulators of osteoclastogenesis and mechanisms by which these factors suppress bone resorption.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Regulation of osteoclast differentiation. Osteoclasts are derived from myeloid precursors. Macrophage colony-stimulating factor (M-CSF) induces myeloid precursors to differentiate to osteoclast precursors that express RANK (Receptor activator of NF-κB) and TREM2 (Triggering receptor expressed by myeloid cells-2) receptors. Upon RANK ligand (RANKL) stimulation and ITAM (Immunoreceptor tyrosine-based activation motif) activation, osteoclast precursors undergo further differentiation to mononuclear osteoclasts with NFATc1 (Nuclear factor of activated T cells, cytoplasmic 1) induction and express osteoclast-related genes such as those encoding TNF-receptor associated protein (TRAP), cathepsin K (CtsK) and αvβ3. Mononuclear osteoclasts then fuse to multinuclear osteoclasts and function as polarized bone resorbing cells. This process of osteoclast differentiation is regulated by various transcription factors and exogenous factors at different stages. Inflammatory factors that promote osteoclastogenesis are shown in red. Inhibitors of osteoclastogenesis are shown in blue. Calc, calcitonin; Calc R, calcitonin receptor; CSF-1R, colony stimulating factor 1 receptor; DC-STAMP, dendritic cell-specific transmembrane protein; ECM, extracellular matrix; GM-CSF, granulocyte-macrophage colony-stimulating factor; M-CSF, macrophage colony-stimulating factor; MITF, microphthalmia-associated transcription factor; OPG, osteoprotegerin; TLR, Toll-like receptor.
Figure 2
Figure 2
Transcriptional regulatory network for osteoclastogenesis. RANK (Receptor activator of NF-κB) signaling together with calcium signaling drives expression of NFATc1 (Nuclear factor of activated T cells, cytoplasmic 1) and its targets, resulting in osteoclastogenesis. This process also requires releasing the 'brakes' on NFATc1 expression and osteoclastogenesis that are imposed by transcriptional repressors, including inhibitors of differentiation/DNA binding (Ids), MafB (v-maf musculoaponeurotic fibrosarcoma oncogene family protein B), interferon regulatory factor (IRF)-8 and B cell lymphoma 6 (Bcl6). There is crosstalk between the activating and suppressive pathways, as Blimp1 (B lymphocyte-induced maturation protein-1) that is induced by NFATc1 suppresses expression of MafB, IRF-8 and Bcl6. ITAM, immunoreceptor tyrosine-based activation motif; MAPK, mitogen-activated protein kinase.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Braun T, Zwerina J. Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. Arthritis Res Ther. 2011;13:235. - PMC - PubMed
    1. Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone. 2007;40:251–264. doi: 10.1016/j.bone.2006.09.023. - DOI - PubMed
    1. Palmqvist P, Lundberg P, Persson E, Johansson A, Lundgren I, Lie A, Conaway HH, Lerner UH. Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway. J Biol Chem. 2006;281:2414–2429. - PubMed
    1. Yamada A, Takami M, Kawawa T, Yasuhara R, Zhao B, Mochizuki A, Miyamoto Y, Eto T, Yasuda H, Nakamichi Y, Kim N, Katagiri T, Suda T, Kamijo R. Interleukin-4 inhibition of osteoclast differentiation is stronger than that of interleukin-13 and they are equivalent for induction of osteoprotegerin production from osteoblasts. Immunology. 2007;120:573–579. doi: 10.1111/j.1365-2567.2006.02538.x. - DOI - PMC - PubMed
    1. Wei S, Wang MW, Teitelbaum SL, Ross FP. Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kappa B and mitogen-activated protein kinase signaling. J Biol Chem. 2002;277:6622–6630. doi: 10.1074/jbc.M104957200. - DOI - PubMed

Publication types

LinkOut - more resources